This is the authors' abstract. We don't add key points for this paper.
Despite remarkable progress, pharmacotherapy in general, including that for the treatment of depressive conditions, has often ignored the magnitude and clinical significance of the huge interindividual variations in pharmacokinetics and pharmacodynamics, resulting in poor compliance, suboptimal therapeutic effects, and treatment resistance. Advances in pharmacogenomics and computer modeling technologies hold promise for achieving the goals of "individualized" ("personalized") medicine. However, the challenges for realizing such goals remain substantial. These include the packaging and interpretation of genotyping results, changes in medical practice (innovation diffusion), and infrastructural, financing, ethical, and organizational issues related to the use of new information.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: